Colorectal Neoplasms
Conditions
Keywords
invasive potential, molecular characterisation of circulating cells
Brief summary
The main objective of this study is to identify and characterize subpopulations of cells with invasive capacity in colorectal cancer from primary tumor, blood and metastatic samples.
Detailed description
Secondary objectives include: * Determine the intrinsic properties essential for the dissemination and chemoresistance of these cells capable of initiating tumors * Identify a molecular signature for potential invasiveness and chemoresistance of cells initiating metastases. * Describe the evolution of patients during 24 months of follow up and correlations with observed cellular profiles. * Enrich the tumor bank of the institution.
Interventions
BIOLOGICALSamples and follow up
Samples: Peroperative blood sample plus primary and metastatic tumor biopsies. Follow-up: disease outcomes assessed at 24 months
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * Patient with adenocarcinoma-type colorectal cancer: * stage III at diagnosis, surgical resection of the primary tumor proposed. * stage IV at diagnosis, surgical resection of the primary tumor and possibly of metastases proposed. * Stage IV who have already undergone surgical excision of the primary tumor, and for whom metastasectomy is now proposed.
Exclusion criteria
* The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * Patients for whom surgical resection of the primary tumor is not considered as an option * PStage IV at diagnosis, but metastasectomy is not considered as an option * Patients with positive HIV, Hepatitis B or Hepatitis C serology
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ability to maintain the cells isolated from colorectal tumors in culture or 3D collagen matrices and then infect these cells to make them express reporter genes: yes/no. | Baseline (Day 0) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serology Hepatitis B | baseline; day 0 | — |
| Serology Hepatitis C | baseline; day 0 | — |
| Location of primary tumor | base line; day 0 | right colon, left colon, transverse colon, sigmoid, rectum |
| Age at diagnosis | baseline, day 0 | — |
| Metastases from the outset: Yes / No | baseline, day 0 | — |
| Resection proposed: yes/no | baseline, day 0 | — |
| Chemotherapy proposed? yes/no | baseline, day 0 | — |
| Number of metastases | 24 months | — |
| Resection performed: yes/no | 24 months | — |
| Number of chemotherapy sessions performed | 24 months | — |
| Serology HIV | baseline; day 0 | — |
| Tumor recurrence: yes/no | 24 months | — |
| Vital status | 24 months | living/deceased |
| Ability to establish tumor xenografts from injected cells: yes/no. | baseline; Day 0 | — |
| Ability to detect subpopulations of tumor cells expressing fluorophores by flow cytometry after isolation: yes/no | baseline; day 0 | — |
| Characterization of mRNA expression profiling and micro-RNA + in vitro EMT cells | baseline; day 0 | — |
| World Health Organisation Score | 24 months | — |
| Tumor staging | 24 months | — |
| Number of surgeries performed | 24 months | — |
| Number of circulating cancer cells per ml blood | baseline; day 0 | — |
| Objective tumoral response to treatment? yes/no | 24 months | — |
Countries
France
Outcome results
None listed